AutoCRAT (www.autocrat.eu) is developing rational and sustainable cell and cell-based/guided therapies for osteoarthritis (OA) with the concurrent development of closed, scalable and regulatory-compliant automated systems for aseptic therapeutic moieties (whether cell or cell-based manufacturing) for the delivery of therapeutics to patients. The project addresses the following therapeutic challenges: 1) to identify optimal, next-generation therapies for OA and cartilage repair whether cell-mediated or cell-guided, 2) the economic, sustainable, regulatory-compliant production of a) allogeneic donor-derived MSC, b) sustainable and reproducible human induced pluripotent stem cells (iPSC)-derived MSC and human iPSC-derived articular chondrocytes and c) their secreted therapeutic cargo, and 3) to progress the translation and delivery of the therapies by complying with regulatory requirements and creating a sustainable commercialisation pathway to ensure that patients benefit. AutoCRAT delivers novel therapies at scale by addressing cost-effective, automated production of developed therapeutic entities to deliver consistent clinical products with minimised contamination, maximised scale and reduced cost of goods. AutoCRAT outputs are designed with regulatory compliance and effective, affordable delivery to a large number of patients as underpinning elements. The technologies developed to produce human therapeutic cells or secreted factors extend beyond OA and address many diseases that can be treated by MSC. AutoCRAT has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 874671. The material presented and views expressed here are the responsibility of the author(s) only. The EU Commission takes no responsibility for any use made of the information set out.
PD-MitoQUANT (https://www.pdmitoquant.eu/) is an Innovative Medicines Initiative (IMI) project that brings together academic experts, SMEs, pharmaceutical companies from the European Federation of Pharmaceutical Industries and Associations (EFPIA) and patient advocacy organisation Parkinson’s UK to: (i) improve our understanding of mitochondrial dysfunction in Parkinson’s, (ii) identify and validate molecular drivers and mechanisms in Parkinson’s, and (iii) discover innovative therapeutic targets that can be further progressed by the EFPIA partners in the future. This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 821522. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and Parkinson’s UK. The material presented and views expressed here reflect the author’s view and neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained herein.
We will develop, validate and demonstrate a novel nanotechnology-enhanced optoacoustic imaging (OAI) platform for regenerative medicine. Gold nanostars amplify signal response in OAI. This property enables mesenchymal stem cells and MSC-derived extracellular vesicles labelled with gold nanostars to be tracked at unprecedented depth and sensitivity upon infusion in the arthritic joints of large animals. STARSTEM has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 761214. The material presented and views expressed here are the responsibility of the author(s) only. The EU Commission takes no responsibility for any use made of the information set out.